For the most up to date information on COVID-19 please visit the Department of Health website. Learn more about how the AIHW is assisting the COVID-19 response and how our other work is affected. Our Covid-19 related resources page includes a list of some existing resources which may be useful when researching issues related to COVID-19.
Australian Institute of Health and Welfare 2019. National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018. Cat. no. HSE 218. Canberra: AIHW. Viewed 30 May 2020, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018
Australian Institute of Health and Welfare. (2019). National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018. Retrieved from https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018
National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018. Australian Institute of Health and Welfare, 03 April 2019, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018
Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018 [Internet]. Canberra: Australian Institute of Health and Welfare, 2019 [cited 2020 May. 30]. Available from: https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018
Australian Institute of Health and Welfare (AIHW) 2019, National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018, viewed 30 May 2020, https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018
Get citations as an Endnote file:
View other formats
On a snapshot day in 2018, just over 50,000 clients received pharmacotherapy treatment for their opioid dependence at 2,852 dosing points across Australia. There were 3,168 authorised prescribers of opioid pharmacotherapy drugs.
There were 3,168 authorised opioid pharmacotherapy prescribers
50,597 clients received opioid pharmacotherapy treatment nationally
2 in 3 opioid pharmacotherapy clients were male
1 in 10 opioid pharmacotherapy clients identified as being Aboriginal and/or Torres Strait Islander
Dependence on opioid drugs (which include codeine, heroin and oxycodone) is associated with a range of health and social problems that affect individual drug users, their family and friends, and the wider public. Treatment with an opioid pharmacotherapy drug, such as methadone or buprenorphine, can reduce drug cravings (NDARC 2004) and improve physical and mental health and social and economic participation, including a reduction in drug-related crime (Ritter A & Chalmers J 2009).
The National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection provides information on a snapshot day in June 2018 on clients receiving opioid pharmacotherapy treatment, the health professionals prescribing opioid pharmacotherapy drugs, and the dosing points (such as pharmacies) that clients attend to receive their medication.
For more details about the collection, refer to the Technical notes.
Refer to the National Opioid Pharmacotherapy Statistics Annual Data collection data quality statement for more information.
Opioids are chemical substances that have a morphine-type action in the body. They are most commonly used for pain relief, but they are addictive and can lead to drug dependence. They include:
Opioid drugs can be:
From 1 February 2018, all codeine containing analgesics have required a prescription.
Opioid drug use and dependence is associated with a range of health and social problems including:
Drug dependence is characterised by drug seeking and using, but people experience it in various ways. The International statistical classification of diseases and related health problems, 10th revision (ICD-10) (WHO 2010) defines 'dependence syndrome' due to the use of opioids as:
'A cluster of behavioural, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal state (Code F11.2).'
Opioid pharmacotherapy treatment is one of the main treatment types used for opioid drug dependence and involves replacing the opioid drug of dependence with a legally obtained, longer-lasting opioid that is taken orally.
In Australia, 3 medications are registered for long-term maintenance treatment for opioid-dependent people:
These drugs, known as opioid pharmacotherapies, reduce withdrawal symptoms, the desire to take opioids, and the euphoric effect of taking opioids. Treatment with these drugs is administered according to the law of the relevant state or territory, and within a framework that includes medical, social and psychological treatment.
The Australian Government Department of Health, as part of the National Drug Strategy, published the National guidelines for medication-assisted treatment of opioid dependence (DoH 2014) to provide a broad policy context and framework for state and territory policies and guidelines that are concerned with the medication-assisted treatment of opioid dependence.
DoH (Department of Health) 2014. National guidelines for medication-assisted treatment of opioid dependence. Canberra: DoHA for National Drug Strategy. Viewed 16 January 2019.
NDARC (National Drug and Alcohol Research Centre) 2004. Treatment options for heroin and other opioid dependence: a guide for frontline workers. Canberra: Commonwealth Department of Health and Ageing for the National Drug Strategy. Viewed 16 January 2019.
NSW Clinical Guidelines: Treatment of Opioid Dependence – 2018. Viewed 18 January 2019.
Ritter A & Chalmers J 2009. Polygon: the many sides to the Australian opioid pharmacotherapy maintenance system. ANCD research paper no. 18. Canberra: Australian National Council on Drugs.
Roxburgh A, Bruno R, Larance B & Burns L 2011. Prescription of opioid analgesics and related harms in Australia. Medical Journal of Australia 195:280–284.
WHO (World Health Organization) 2010. Mental and behavioural disorder due to the use of opioids: dependence syndrome. ICD-10: International statistical classification of diseases and related health problems. Viewed 16 January 2019.
We'd love to know any feedback that you have about the AIHW website, its contents or reports.
The browser you are using to browse this website is outdated and some features may not display properly or be accessible to you. Please use a more recent browser for the best user experience.